Cetuximab + Paclitaxel
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Urologic Neoplasm
Conditions
Urologic Neoplasm
Trial Timeline
Aug 1, 2006 → Sep 1, 2012
NCT ID
NCT00350025About Cetuximab + Paclitaxel
Cetuximab + Paclitaxel is a phase 2 stage product being developed by Bristol Myers Squibb for Urologic Neoplasm. The current trial status is completed. This product is registered under clinical trial identifier NCT00350025. Target conditions include Urologic Neoplasm.
What happened to similar drugs?
0 of 1 similar drugs in Urologic Neoplasm were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00350025 | Phase 2 | Completed |
Competing Products
16 competing products in Urologic Neoplasm
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 32 |
| Mirabegron + Solifenacin succinate + Placebo | Astellas Pharma | Phase 2 | 35 |
| Mirabegron + Solifenacin succinate | Astellas Pharma | Phase 3 | 40 |
| Gemcitabine | Eli Lilly | Phase 2 | 35 |
| pemetrexed | Eli Lilly | Phase 2 | 35 |
| ALIMTA + gemcitabine | Eli Lilly | Phase 2 | 35 |
| BBI503 | Sumitomo Pharma | Phase 2 | 27 |
| Pembrolizumab Injection [Keytruda] | Merck | Phase 2 | 42 |
| Carboplatin/Paclitaxel + Pembrolizumab | Merck | Phase 2 | 42 |
| zoledronic acid | Novartis | Phase 2 | 27 |
| mycophenolate mofetil | Roche | Phase 1 | 29 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 42 |
| CBT101 + Placebo | Brain Biotech | Phase 1 | 26 |
| OGX-427 600 mg + OGX-427 1000 mg + Placebo + Gemcitabine + Cisplatin + Carboplatin | Achieve Life Sciences | Phase 2 | 25 |
| S-8184 Paclitaxel Injectable Emulsion + Experimental Arm: TOCOSOL Paclitaxel | Achieve Life Sciences | Phase 2 | 25 |
| Stem Cell | Brain Biotech | Phase 1 | 11 |